Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting

/PRNewswire/ -- Taiho Oncology, Inc. announced today updated results of the Phase 2 FOENIX-CCA2 trial of futibatinib, confirming results observed in an earlier...

Related Keywords

Oakville ,Ontario ,Canada ,United States ,New Jersey ,Massachusetts ,Boston ,Switzerland ,Chicago ,Illinois ,Canadian ,American ,Lipika Goyal ,Judy Kay Moore ,Volker Wacheck ,Taiho Pharmaceutical Co Ltd ,American Society Of Clinical Oncology ,Hospital Cancer Center ,Drug Administration ,Taiho Oncology Inc ,Cholangiocarcinoma Foundation ,Prnewswire Taiho Oncology Inc ,Otsuka Holdings Co Ltd ,Clinical Development ,American Cancer Society ,New Drug Application ,Clinical Oncology ,Annual Meeting ,Massachusetts General Hospital Cancer Center ,Vice President ,Taiho Oncology ,Prescription Drug User Fee Act ,Breakthrough Therapy Designation ,Oncology Media Contact ,Reviews Gastroenterology ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,